Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - H.C. Wainwright has reiterated a Buy rating and $35.00 price target on MiNK Therapeutics (NASDAQ:INKT), a $256 million market cap biotech company, following the publication of a notable case study in Nature’s Oncogene on July 11. According to InvestingPro data, the stock has surged over 820% year-to-date, with analyst targets ranging from $35 to $70.
The published case details a 49-year-old male patient with germ cell neoplasm who achieved complete remission after receiving a single dose of MiNK’s agenT-797 therapy combined with nivolumab. The patient had previously failed multiple treatments including platinum-based chemotherapy, autologous stem cell transplant, and several immune checkpoint inhibitors. InvestingPro analysis indicates the company maintains a moderate debt level with a total debt to capital ratio of just 0.02, providing financial flexibility for continued clinical development.
The patient’s response was described as a complete clinical, radiologic, and biochemical remission, with donor iNKT cells remaining detectable for up to six months post-infusion. The treatment was well-tolerated with no cytokine release syndrome or graft-versus-host disease observed.
This case represents the second notable responder to agenT-797 plus anti-PD-1 therapy, following a second-line gastric cancer patient who achieved 42% tumor reduction with more than nine months of progression-free survival after a single infusion.
MiNK Therapeutics has reported that survival beyond 12 months has already been observed in several patients in its ongoing Phase 2 trial in second-line gastric cancer, comparing favorably to the 9.6-month median overall survival seen with ramucirumab/paclitaxel in the RAINBOW Phase 3 trial. While the company is not yet profitable, with an EBITDA of -$9.78M in the last twelve months, InvestingPro reports strong momentum scores and identifies 12 additional key factors that could impact the stock’s future performance. Get the full analysis and discover more investment opportunities with InvestingPro’s comprehensive research reports, available for over 1,400 US stocks.
In other recent news, MiNK Therapeutics, Inc. has reported a significant achievement with its iNKT cell therapy, agenT-797, demonstrating a complete remission in a patient with metastatic testicular cancer. The patient, who had previously undergone multiple unsuccessful treatments, showed no evidence of disease for over two years following a single infusion of agenT-797 combined with nivolumab. This breakthrough adds to MiNK’s clinical evidence supporting the therapy’s potential in treating solid tumors, with further data from a Phase 2 trial in gastric cancer indicating extended survival in patients resistant to checkpoint inhibitors. Additionally, MiNK Therapeutics has secured a grant from the National Institute of Allergy and Infectious Diseases to advance its allo-iNKT cell therapy platform aimed at preventing graft-versus-host disease, a serious condition post-stem cell transplantation. This grant will support collaboration with the University of Wisconsin to enhance the therapy’s development. MiNK is also focusing on other immune technologies, including T cell receptor-based therapies. These developments highlight MiNK’s ongoing efforts in innovative therapies for various medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.